After a decent first half, the drug and biotech sector saw a major downturn in the second half due to disappointing third-quarter sales and profits, guidance cuts, pipeline setbacks and the appointment of Robert F. Kennedy Jr., a vaccine skeptic, as the head of Health and Human Services.Nonetheless, innovation is at its peak for the industry, with key spaces like diabetes/obesity, gene therapy, inflammation and neuroscience attracting investor attention. FDA approvals continued at a rapid pace throughout 20 ...

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the 'long' context, investors will essentially be "buying high, but hoping to sell even higher." And for investors following this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving in that direction. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.Even ...

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is Arcellx, Inc. (ACLX) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question. Arcellx, Inc. is a member of our Medical group, which includes 1024 different companies and currently sits at #3 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 diffe ...

Arcellx, Inc. (ACLX) came out with a quarterly loss of $0.48 per share versus the Zacks Consensus Estimate of a loss of $0.54. This compares to loss of $0.81 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 11.11%. A quarter ago, it was expected that this company would post a loss of $0.54 per share when it actually produced a loss of $0.51, delivering a surprise of 5.56%. Over the last four quarters, the company has surpassed ...

| --- | --- | |-----------------------------------------------------------------------|-----------| | | | | UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 | | | | FORM 10-Q | (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission File Number: ...

Exhibit 99.1 Arcellx Provides Third Quarter 2024 Financial Results and Business Highlights — Recently released ASH abstracts for the company's Phase 1 and iMMagine-1 studies investigating anito-cel in relapsed or refractory multiple myeloma patients continue to demonstrate durability and a manageable safety profile — — 30.2-month median progression-free survival with a median follow-up of 38.1 months in the Phase 1 study of anito-cel; median overall survival not reached — — Preliminary results from 58 patie ...

Arcellx, Inc. (ACLX) shares rallied 6.7% in the last trading session to close at $92.98. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 7.8% gain over the past four weeks. The sudden rise in the stock price can be attributed to the positive investor mindset regarding the potential of Arcellx's clinical-stage oncology pipeline. The company is currently evaluating several candidates in separate clinical studie ...

Floaria Bicher/iStock via Getty Images Arcellx, Inc. (NASDAQ:ACLX) is a biotechnology company with innovative oncology CAR-T cell therapies. ACLX leverages proprietary platforms, including D-Domain, ddCAR, and ARC-SparX, to enhance the immune system's capabilities to detect and kill cancer cells. Currently, ACLX’s leading product candidate is anitocabtagene autoleucel [anito-cel], which shows promising results in patients with relapsed/refractory multiple myeloma [r/r MM]. These results seem to also hol ...

Arcellx, Inc. (ACLX) came out with a quarterly loss of $0.51 per share versus the Zacks Consensus Estimate of a loss of $0.54. This compares to loss of $0.50 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 5.56%. A quarter ago, it was expected that this company would post a loss of $0.51 per share when it actually produced a loss of $0.14, delivering a surprise of 72.55%. Over the last four quarters, the company has surpassed ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission File Number: 001-41259 ARCELLX, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 47-2855917 (State or other jurisdi ...